Cargando…

A single dose of the Biontech/Pfizer BNT162b2 vaccine protected elderly residents from severe COVID‐19 during a SARS‐coronavirus‐2 outbreak in a senior citizen home in Germany

Background: A total of 62/66 (93.9%) residents in a senior citizen home in Bremen, Germany, received the first dose of the Biontech/Pfizer vaccine BNT162b2 on December 27th 2020. After routine severe acute respiratory syndrome coronavirus 2 (SARS‐CoV‐2) antigen tests showed positive results on Janua...

Descripción completa

Detalles Bibliográficos
Autores principales:	Schwarzer, Rolf, Freys, Sabine D., Neuwinger, Nick, Beikert, Nina, Eberspächer, Bettina, Edelmann, Anke, Zuchowski, Marta, Slothouwer, Inga, Stein, Angela, Theil, Kathrin, Menzel, Peter, Hofmann, Jörg
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	John Wiley and Sons Inc. 2021
Materias:	Short Reports
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8589371/ https://www.ncbi.nlm.nih.gov/pubmed/34528766 http://dx.doi.org/10.1002/iid3.532

Ejemplares similares

A racing heart post‐Pfizer/BioNTech BNT162b2
por: Teo, Hooi Khee, et al.
Publicado: (2022)

Analysis of intracranial haemorrhage following tozinameran (BNT162b2, Pfizer-BioNTech)
por: Hamada, Yohhei
Publicado: (2021)

Potential Triggers for Thrombocytopenia and/or Hemorrhage by the BNT162b2 Vaccine, Pfizer-BioNTech
por: Okada, Yusuke, et al.
Publicado: (2021)

Mechanisms of innate and adaptive immunity to the Pfizer-BioNTech BNT162b2 vaccine
por: Li, Chunfeng, et al.
Publicado: (2022)

Syncope following Pfizer BioNTech (bnt162b2) vaccination unmasking Brugada syndrome
por: Altermanini, Mohammad, et al.
Publicado: (2023)

Neutrophilic urticarial dermatosis following BNT162b2 (Pfizer–BioNTech) COVID‐19 vaccination
por: Matsubara, Akihiro, et al.
Publicado: (2021)

Cerebral Venous Sinus Thrombosis After Pfizer-BioNTech COVID-19 (BNT162b2) Vaccination
por: Cheng, Newman
Publicado: (2021)

Lung squamous cell carcinoma with hemoptysis after vaccination with tozinameran (BNT162b2, Pfizer‐BioNTech)
por: Sumi, Toshiyuki, et al.
Publicado: (2021)

Immune thrombocytopenia associated with Pfizer-BioNTech’s BNT162b2 mRNA COVID-19 vaccine
por: Akiyama, Hiroaki, et al.
Publicado: (2021)

Vulvar Aphthous Ulcer in an Adolescent After Pfizer-BioNTech (BNT162b2) COVID-19 Vaccination
por: Wojcicki, Anna V., et al.
Publicado: (2022)

Efficacy of Vaccine BNT162b2 (Pfizer-BioNTech) in Individuals with Waldenstrom's Macroglobulinemia and Follicular Lymphoma in Australia
por: Beaton, Brendan, et al.
Publicado: (2021)

Pfizer-BioNTech COVID-19 Vaccine (BNT162b2) Side Effects: A Systematic Review
por: Dighriri, Ibrahim M, et al.
Publicado: (2022)

Development of Flat Warts on the Cheeks after BioNTech-Pfizer BNT162b2 Vaccine: Is There a Correlation?
por: Cazzato, Gerardo, et al.
Publicado: (2022)

Potential adverse events in Japanese women who received tozinameran (BNT162b2, Pfizer-BioNTech)
por: Shimazawa, Rumiko, et al.
Publicado: (2021)

Humoral Response to SARS-CoV-2-Vaccination with BNT162b2 (Pfizer-BioNTech) in Patients on Hemodialysis
por: Jahn, Michael, et al.
Publicado: (2021)

Decline of Humoral Responses 6 Months after Vaccination with BNT162b2 (Pfizer–BioNTech) in Patients on Hemodialysis
por: Jahn, Michael, et al.
Publicado: (2022)

Side effects of Pfizer/BioNTech (BNT162b2) COVID-19 vaccine reported by the Birzeit University community
por: Abukhalil, Abdallah Damin, et al.
Publicado: (2023)

Effectiveness of the BNT162b2 (Pfizer-BioNTech) Vaccine in Children and Adolescents: A Systematic Review and Meta-Analysis
por: Sabu, Jewel Maria, et al.
Publicado: (2022)

A Case of Idiopathic Thrombocytopenic Purpura After Booster Dose of BNT162b2 (Pfizer-Biontech) COVID-19 Vaccine
por: Malayala, Srikrishna V, et al.
Publicado: (2021)

Comparative effectiveness over time of the mRNA-1273 (Moderna) vaccine and the BNT162b2 (Pfizer-BioNTech) vaccine
por: Islam, Nazmul, et al.
Publicado: (2022)

Evaluation of hematological parameters and thrombocytopenia following Pfizer-BioNTech (BNT162b2) SARS-CoV-2 vaccination
por: Algaissi, Abdullah, et al.
Publicado: (2022)

Variation in the Humoral Immune Response Induced by the Administration of the BNT162b2 Pfizer/BioNTech Vaccine: A Systematic Review
por: Cortés-Sarabia, Karen, et al.
Publicado: (2022)

Friend or foe—The Pfizer‐BioNTech (BNT162b2) vaccination: A case report of reversible acute acalculous cholecystitis
por: Wahlen, Bianca Maria, et al.
Publicado: (2022)

Cerebellar and brainstem stroke possibly associated with booster dose of BNT162b2 (Pfizer-BioNTech) COVID-19 vaccine
por: Thomas, Michael George, et al.
Publicado: (2023)

Stability testing of the Pfizer-BioNTech BNT162b2 COVID-19 vaccine: a translational study in UK vaccination centres
por: Kudsiova, Laila, et al.
Publicado: (2021)

Impaired Humoral Response in Renal Transplant Recipients to SARS-CoV-2 Vaccination with BNT162b2 (Pfizer-BioNTech)
por: Korth, Johannes, et al.
Publicado: (2021)

Recurrent erythema nodosum after the second dose of the Pfizer-BioNTech BNT162b2 COVID-19 messenger RNA vaccine
por: Wu, Xiaotian, et al.
Publicado: (2021)

Clinicopathological Characteristics of Inflammatory Myositis Induced by COVID-19 Vaccine (Pfizer-BioNTech BNT162b2): A Case Report
por: Kim, Ji Hyoun, et al.
Publicado: (2022)

Unusual Case of Painful Glossitis and Xerostomia Following Vaccination with Pfizer-BioNTech SARS-CoV-2 (BNT162b2)
por: Tan, Elina, et al.
Publicado: (2022)

Pfizer-BioNTech (BNT162b2), Moderna (mRNA-1273) COVID-19 mRNA vaccines and hypersensitivity reactions
por: Haq, Hannah N., et al.
Publicado: (2022)

Acute adrenal insufficiency in a patient with panhypopituitarism after vaccination against COVID-19 (BNT162b2 Pfizer-BioNTech)
por: González López, Javier, et al.
Publicado: (2022)

Intracranial Hemorrhage After Pfizer-BioNTech (BNT162b2) mRNA COVID-19 Vaccination: A Case Report
por: Yangi, Kivanc, et al.
Publicado: (2023)

Adverse Events Following the BNT162b2 mRNA COVID-19 Vaccine (Pfizer-BioNTech) in Aotearoa New Zealand
por: Walton, Muireann, et al.
Publicado: (2023)

Pseudo-Anaphylactic Reactions to Pfizer BNT162b2 Vaccine: Report of 3 Cases of Anaphylaxis Post Pfizer BNT162b2 Vaccination
por: Lim, Xin Rong, et al.
Publicado: (2021)

Systemic capillary leak syndrome (SCLS) after receiving BNT162b2 mRNA COVID-19 (Pfizer-BioNTech) vaccine
por: Inoue, Masatoshi, et al.
Publicado: (2022)

Safety of mRNA BNT162b2 COVID-19 (Pfizer-BioNtech) vaccine in children aged 5-11 years: Correspondence
por: Mungmunpuntipantip, Rujittika, et al.
Publicado: (2022)

The Effects of CoronaVac (Sinovac) and BNT162b2 (BioNTech/Pfizer) Vaccination on Oncologic (18)F-FDG PET/CT Studies
por: Şan, Hüseyin, et al.
Publicado: (2022)

Hypereosinophilic Syndrome Following the BNT162b2 (BioNTech/Pfizer) Vaccine Successfully Treated with Mepolizumab: A Case Report and Review of the Literature
por: Hoxha, Ariela, et al.
Publicado: (2023)

Exacerbations of Idiopathic Systemic Capillary Leak Syndrome following BNT162b2 mRNA COVID-19 Vaccine (Pfizer-BioNTech)
por: Akiyama, Yutaro, et al.
Publicado: (2023)

Anti–severe acute respiratory syndrome coronavirus 2 antibodies induced in breast milk after Pfizer-BioNTech/BNT162b2 vaccination
por: Kelly, Jeannie C., et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_g40ggcifckr8hsqupkdsjge03c